Compounds > valproic acid

valproic acid and lapatinib

valproic acid has been researched along with lapatinib in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S1

Reviews

1 review(s) available for valproic acid and lapatinib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for valproic acid and lapatinib

ArticleYear
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
    Cancer biology & therapy, 2013, Oct-01, Volume: 14, Issue:10

    Topics: Animals; Anoikis; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Brain Neoplasms; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Indoles; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Valproic Acid; Xenograft Model Antitumor Assays

2013